Some of these drugs approved for advanced stages of melanoma include nivolumab and pembrolizumab (PD-1 inhibitors), ipilimumab (anti-CTLA4 antibody) and the oncolytic virus talimogene laherparepvec (TVEC). Here, CTLA4 is linked to melanoma.